Trial Profile
Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pembrolizumab (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- 16 Nov 2023 Planned End Date changed from 31 Oct 2023 to 28 Feb 2024.
- 05 Sep 2023 Planned End Date changed from 1 Aug 2023 to 31 Oct 2023.
- 06 Apr 2023 Planned End Date changed from 31 Dec 2022 to 1 Aug 2023.